Loading
Life sciences · Journal article
Food Science and Human Wellness · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Non-alcoholic fatty liver disease (NAFLD) remains a major health challenge, and although fucoxanthin (Fx) shows therapeutic potential, its poor stability and low bioavailability limit clinical application. In this study, a novel delivery system for Fx, a marine-derived xanthophyll carotenoid with anti-obesity, anti-diabetic, and hepatoprotective properties, was developed by encapsulating it within coaxial electrospun nanofibers. GZ12/ZFx exhibited uniform morphology with a distinct core–shell structure and superior encapsulation efficiency, coaxial electrospinning increased the Fx encapsulation by 1.17 times. In a high-fat diet-induced obese mouse model, GZ12/ZFx significantly outperformed free fucoxanthin and uniaxial nanofibers in improving metabolic parameters, reducing hepatic lipid accumulation, and modulating gut microbiota. The GZ12/Fx group limited weight increase to 3.64 g, while GZ12/ZFx performed only 3.02 g gain. The measurement results of lipid-related indicators in the serum indicated that the intervention of GZ12/ZFx was much more effective than that of GZ12/Fx. The reduction rates of TC and TG were 1.17 times and 1.75 times higher, respectively. The advanced delivery systems significantly enhanced the bioactivity of Fx, demonstrating improved metabolic outcomes and favorable safety profiles. These findings provide insights into designing effective food-grade delivery systems for hydrophobic bioactives and their potential in the intervention of NAFLD.